*For those switching to dolutegravir plus rilpivirine—must be taken with a meal.
†Administer TIVICAY 2 hours before or 6 hours after taking antacids, polyvalent cation-containing products or laxatives, sucralfate, oral supplements containing iron or calcium, or buffered medications. Alternatively, oral calcium and iron supplements (including multivitamins containing calcium or iron) can be taken with TIVICAY if coadministered with a meal.
DTG: AN INSTI WITH FLEXIBILITY
IN PRESCRIBING OPTIONS
‡For adults and pediatric patients weighing at least 30 kg.
§With rilpivirine 25 mg for adults who are virologically suppressed (HIV-1 RNA <50 copies per mL) on a stable antiretroviral regimen for ≥6 months.
DTG=dolutegravir; INSTI=integrase strand transfer inhibitor; ARVs=antiretrovirals.
Perform pregnancy testing before initiation of TIVICAY in adolescents and adults of childbearing potential
Safety and efficacy of TIVICAY have not been established in pediatric patients who are INSTI experienced with documented or clinically suspected resistance to other INSTIs (raltegravir, elvitegravir)
References: 1. Min S, Song I, Borland J, et al. Pharmacokinetics and safety of S/GSK1349572, a next-generation HIV integrase inhibitor, in healthy volunteers. Antimicrob Agents Chemother. 2010;54(1):254-258. 2. Data on file, ViiV Healthcare. 3. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1 infected adults and adolescents. Department of Health and Human Services. http://aidsinfo.nih.gov/contentfiles/lvguidelines/adultandadolescentgl.pdf. Accessed July 30, 2019. 4. HCV guidance: recommendations for testing, managing, and treating hepatitis C. American Association for the Study of Liver Diseases and Infectious Diseases Society of America. https://www.hcvguidelines.org/unique-populations/hiv-hcv. Accessed July 30, 2019. 5. Luetkemeyer AF, McDonald C, Ramgopal M, et al. 12 weeks of daclatasvir in combination with sofosbuvir for HIV-HCV coinfection (ALLY-2 study): efficacy and safety by HIV combination antiretroviral regimens. Clin Infect Dis. 2016;62(12):1489-1496. 6. Garrison K, Custodio J, Pang P, et al. Drug interactions between anti-HCV antivirals ledipasvir/sofosbuvir and integrase strand transfer inhibitor-based regimens [abstract 71]. Presented at:16th International Workshop on Clinical Pharmacology of HIV & Hepatitis Therapy; May 26-28, 2015; Washington, DC. 7. Harvoni [package insert]. Gilead Sciences, Inc.: Foster City, CA; November 2017. 8. Olysio [package insert]. Janssen Therapeutics: Titusville, NJ; November 2017. 9. Rockstroh JK, Nelson M, Katlama C, et al. Efficacy and safety of grazoprevir (MK-5172) and elbasvir (MK-8742) in patients with hepatitis C virus and HIV co-infection (C-EDGE CO-INFECTION): a non-randomised, open-label trial. Lancet HIV. 2015;2(8):e319-e327. 10. Yeh W, Feng HP, Guo Z, et al. Drug-drug interaction between HCV inhibitors grazoprevir/elbasvir with dolutegravir [abstract 522]. Presented at: Conference on Retroviruses and Opportunistic Infections (CROI); February 23-26, 2015; Seattle, WA. 11. Song I, Jerva F, Zong J, et al. Evaluation of drug interactions between dolutegravir and daclatasvir in healthy subjects [abstract 79]. Presented at: 16th International Workshop on Clinical Pharmacology of HIV & Hepatitis Therapy; May 26-28, 2015; Washington, DC. 12. Daklinza [package insert]. Bristol-Myers Squibb Company: Princeton, NJ; November 2017. 13. Khatri A, Trinh R, Zhao W, et al. Drug-drug interactions of ombitasvir/paritaprevir/r plus dasabuvir with dolutegravir or abacavir plus lamivudine. Presented at: Clinical Pharmacology of HIV and Hepatitis Therapy; May 26-28, 2015; Washington, DC. 14. Viekira Pak [package insert]. AbbVie Inc: North Chicago, IL; July 2018. 15. Epclusa [package insert]. Gilead Sciences, Inc.: Foster City, CA; November 2017. 16. Vosevi [package insert]. Gilead Sciences, Inc.; Foster City, CA; November 2017. 17. Mavyret [package insert]. Abbvie, Inc: North Chicago, IL; June 2019.
YOU MAY ALSO BE INTERESTED IN